10:55 AM EST - Avicanna Inc. : Announced the initiation of new Phase I randomized, double-blinded, placebo-controlled, dose-finding clinical trial led by researchers at the University of Calgary’s Cumming School of Medicine. Avicanna Inc.
shares T.AVCN are trading unchanged at $0.18.
